BR122016006880B8 - forma de dosagem contendo pantoprazol como ingrediente ativo - Google Patents

forma de dosagem contendo pantoprazol como ingrediente ativo

Info

Publication number
BR122016006880B8
BR122016006880B8 BR122016006880A BR122016006880A BR122016006880B8 BR 122016006880 B8 BR122016006880 B8 BR 122016006880B8 BR 122016006880 A BR122016006880 A BR 122016006880A BR 122016006880 A BR122016006880 A BR 122016006880A BR 122016006880 B8 BR122016006880 B8 BR 122016006880B8
Authority
BR
Brazil
Prior art keywords
active ingredient
dosage form
form containing
containing pantoprazole
pantoprazole
Prior art date
Application number
BR122016006880A
Other languages
English (en)
Other versions
BR122016006880B1 (pt
Inventor
Ney Hartmut
Anstett-Klein Isabel
Hartmann Manfred
Schiller Marc
Dietrich Rango
Schäfer-Preuss Sabine
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33436112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR122016006880(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of BR122016006880B1 publication Critical patent/BR122016006880B1/pt
Publication of BR122016006880B8 publication Critical patent/BR122016006880B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção se refere a formas de dosagem que são descritas para administração oral de sal de magnésio de pantoprazol.
BR122016006880A 2003-05-08 2004-05-07 forma de dosagem contendo pantoprazol como ingrediente ativo BR122016006880B8 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP03010328.7 2003-05-08
EP03010328 2003-05-08
EP04001754.3 2004-01-28
EP04001754 2004-01-28
BRPI0410044A BRPI0410044B8 (pt) 2003-05-08 2004-05-07 forma de dosagem contendo pantoprazol como ingrediente ativo
PCT/EP2004/050729 WO2004098594A2 (en) 2003-05-08 2004-05-07 Dosage form containing pantoprazole as active ingredient

Publications (2)

Publication Number Publication Date
BR122016006880B1 BR122016006880B1 (pt) 2020-11-10
BR122016006880B8 true BR122016006880B8 (pt) 2021-05-25

Family

ID=33436112

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122016006880A BR122016006880B8 (pt) 2003-05-08 2004-05-07 forma de dosagem contendo pantoprazol como ingrediente ativo
BRPI0410044A BRPI0410044B8 (pt) 2003-05-08 2004-05-07 forma de dosagem contendo pantoprazol como ingrediente ativo

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0410044A BRPI0410044B8 (pt) 2003-05-08 2004-05-07 forma de dosagem contendo pantoprazol como ingrediente ativo

Country Status (27)

Country Link
US (2) US20060240100A1 (pt)
EP (2) EP2316454B9 (pt)
JP (2) JP4878284B2 (pt)
KR (2) KR101237742B1 (pt)
AR (1) AR044264A1 (pt)
AU (2) AU2004237363B2 (pt)
BR (2) BR122016006880B8 (pt)
CA (1) CA2489140C (pt)
CL (1) CL2004000983A1 (pt)
CY (2) CY1113128T1 (pt)
DK (2) DK1624869T3 (pt)
EA (2) EA016824B1 (pt)
ES (2) ES2390342T3 (pt)
HK (1) HK1090546A1 (pt)
HR (2) HRP20120754T1 (pt)
IL (2) IL171365A (pt)
MX (1) MXPA05000411A (pt)
NO (1) NO337921B1 (pt)
NZ (1) NZ543181A (pt)
PE (1) PE20050199A1 (pt)
PL (2) PL1624869T3 (pt)
PT (2) PT2316454E (pt)
RS (1) RS53443B (pt)
SI (2) SI1624869T1 (pt)
TW (1) TW200509992A (pt)
WO (1) WO2004098594A2 (pt)
ZA (1) ZA200508202B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
PL1746980T3 (pl) 2004-05-07 2012-03-30 Nycomed Gmbh Farmaceutyczna postać dawkowania zawierająca peletki i sposób jej wytwarzania
AR054358A1 (es) * 2005-05-13 2007-06-20 Combino Pharm Sl Formulaciones que contienen pantoprazol libre de acido y sus sales
EP1747776A1 (en) * 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising granular pantoprazole
TWI519322B (zh) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
WO2010018593A2 (en) * 2008-07-03 2010-02-18 Torrent Pharmaceuticals Ltd. Gastric acid resistant benzimidazole multiple unit tablet composition
MX2013000827A (es) * 2010-07-22 2013-06-28 Lupin Ltd Composicion de tableta de unidad multiple.
KR101787481B1 (ko) 2010-10-21 2017-10-18 롯데정밀화학 주식회사 장용성 경질 캡슐용 조성물 및 상기 조성물을 사용하여 제조된 장용성 경질 캡슐
ITMI20111168A1 (it) * 2011-06-27 2012-12-28 Professional Dietetics Srl Composizioni farmaceutiche comprendenti idrossipropilmetilcellulosa e/o acido ialuronico e loro uso
US20150209432A1 (en) * 2012-07-26 2015-07-30 Lupin Limited Pharmaceutical compositions of proton pump inhibitor
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
AU2017339246B2 (en) * 2016-10-06 2020-07-23 Jubilant Generics Limited Delayed release pharmaceutical composition of pantoprazole and process for preparation thereof
US12102624B2 (en) 2020-08-26 2024-10-01 Nivagen Pharmaceuticals, Inc. Pantoprazole compositions and methods
WO2023214016A1 (en) * 2022-05-06 2023-11-09 Evonik Operations Gmbh Dosage form with drug release at ph 3 to 6 using double coating system with at least one release acceleration agent

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
IL85472A (en) 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
JPH0768125B2 (ja) 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
DE3901151A1 (de) 1989-01-17 1990-07-19 Hoechst Ag Stabile pharmazeutische zubereitungen von thienoimidazol-derivaten und deren orale anwendung als magensaeuresekretionshemmer
ES2062634T3 (es) * 1990-08-30 1994-12-16 Senju Pharma Co Composicion con liberacion controlada del farmaco.
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
ES2109377T3 (es) * 1991-12-18 1998-01-16 Warner Lambert Co Proceso para la preparacion de una dispersion solida.
AU6713194A (en) * 1993-04-27 1994-11-21 Sepracor, Inc. Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
ATE414509T1 (de) 1994-07-08 2008-12-15 Astrazeneca Ab Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform
US6132768A (en) * 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE508669C2 (sv) 1996-04-26 1998-10-26 Astra Ab Nytt förfarande
JP3249914B2 (ja) * 1996-06-04 2002-01-28 清水食品株式会社 成型用焼結金型およびその形成方法
EP0866084A3 (en) * 1997-03-21 2002-02-27 Mitsui Chemicals, Inc. Production process of cross-linked polyaspartic acid resin
AU1671799A (en) * 1997-11-28 1999-06-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Medicament preparation in the form of a tablet or pellet for acid-labile active substances
WO1999029320A1 (en) 1997-12-08 1999-06-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel administration form comprising an acid-labile active compound
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
CN100337687C (zh) * 1998-05-15 2007-09-19 沃尼尔·朗伯公司 含有γ－氨基丁酸衍生物的固体组合物及其制备方法
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
JP3274416B2 (ja) * 1998-05-29 2002-04-15 佐藤製薬株式会社 口腔内崩壊性粒状製剤
US7041313B1 (en) 1998-08-12 2006-05-09 Altana Pharma Ag Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CN1361683A (zh) 1999-06-07 2002-07-31 比克·古尔顿·劳姆贝尔格化学公司 含有一种对酸不稳定的活性化合物的新型制剂和药物剂型
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US6346269B1 (en) * 2000-05-08 2002-02-12 Standard Chem. & Pharm. Co., Ltd. Method for preparing an oral formulation containing acid-sensitive drugs and oral formulation made thereby
SI20720A (sl) * 2000-11-20 2002-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nov farmacevtski pripravek v obliki celuloznih kapsul uporaben za derivate benzimidazola
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
CN100335040C (zh) 2000-12-07 2007-09-05 奥坦纳医药公司 含有酸敏感型活性成分的快速崩解片剂
KR20030059318A (ko) * 2000-12-07 2003-07-07 알타나 파마 아게 산 불안정성 활성 성분을 포함하는 현탁액 형태의 약학 제제
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
PL1746980T3 (pl) 2004-05-07 2012-03-30 Nycomed Gmbh Farmaceutyczna postać dawkowania zawierająca peletki i sposób jej wytwarzania
JP4563077B2 (ja) * 2004-05-28 2010-10-13 株式会社ロッテ キャンディ及びその製造方法

Also Published As

Publication number Publication date
HRP20121005T1 (hr) 2013-01-31
PT1624869E (pt) 2012-09-18
JP4878284B2 (ja) 2012-02-15
BRPI0410044A (pt) 2006-04-25
CY1113462T1 (el) 2016-06-22
RS20050818A (en) 2008-04-04
ES2390342T3 (es) 2012-11-12
CA2489140A1 (en) 2004-11-18
IL229510A0 (en) 2013-12-31
IL229510A (en) 2016-09-29
PE20050199A1 (es) 2005-03-26
JP2011126912A (ja) 2011-06-30
KR20060010774A (ko) 2006-02-02
EP2316454B9 (en) 2013-01-02
EP1624869B1 (en) 2012-07-04
PL2316454T3 (pl) 2013-03-29
AU2004237363B2 (en) 2009-12-10
US8703192B2 (en) 2014-04-22
JP2006525286A (ja) 2006-11-09
CA2489140C (en) 2006-10-17
DK1624869T3 (da) 2012-10-01
NZ543181A (en) 2009-10-30
DK2316454T3 (da) 2013-01-21
SI2316454T1 (sl) 2013-01-31
AU2004237363A1 (en) 2004-11-18
JP5162689B2 (ja) 2013-03-13
CL2004000983A1 (es) 2005-03-04
BRPI0410044B8 (pt) 2021-05-25
WO2004098594A3 (en) 2004-12-09
HK1090546A1 (en) 2006-12-29
ES2396197T3 (es) 2013-02-19
AR044264A1 (es) 2005-09-07
NO20055631L (no) 2005-11-29
MXPA05000411A (es) 2005-03-23
TW200509992A (en) 2005-03-16
WO2004098594A2 (en) 2004-11-18
PT2316454E (pt) 2012-12-06
AU2010200905B2 (en) 2012-04-05
CY1113128T1 (el) 2016-04-13
KR101237742B1 (ko) 2013-02-26
RS53443B (en) 2014-12-31
EA201101119A1 (ru) 2011-12-30
ZA200508202B (en) 2006-12-27
SI1624869T1 (sl) 2012-10-30
NO337921B1 (no) 2016-07-11
IL171365A (en) 2014-08-31
EP1624869A2 (en) 2006-02-15
EA016824B1 (ru) 2012-07-30
BR122016006880B1 (pt) 2020-11-10
BRPI0410044B1 (pt) 2019-05-07
HRP20120754T1 (hr) 2012-11-30
EP2316454B1 (en) 2012-09-26
US20060240100A1 (en) 2006-10-26
US20090208571A1 (en) 2009-08-20
AU2010200905A1 (en) 2010-04-01
EA200501697A1 (ru) 2006-06-30
KR20110104124A (ko) 2011-09-21
EA027734B1 (ru) 2017-08-31
PL1624869T3 (pl) 2012-11-30
EP2316454A1 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
NO20043367L (no) Oralt farmasoytisk preparat
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
ECSP11011151A (es) Compuestos purina
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
CR20110110A (es) Composicion farmaceutica
UY33075A (es) Derivados de ciclohexano y usos de los mismos
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
CY1110097T1 (el) Διπλοστοιβαδικο δισκιο για προληψη καρδιαγγειακων συμβαντων
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
EA201170512A1 (ru) Композиция для перорального введения
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
UY33348A (es) Compuestos de furopiridina y usos de los mismos
CO6300935A2 (es) Formulaciones orales e inyectables de compuestos de tetraciclina
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
EA201000882A1 (ru) Соединение, его применение и фармацевтическая композиция, содержащая это соединение
DK2091520T3 (da) Oral doseringsform omfattende trisubstituerede glycerol-forbindelser
NO20083352L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
EA200901205A1 (ru) Фармацевтическая композиция, содержащая соль розиглитазона

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/05/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)